This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Ulipristal acetate was approved by the U.S. Food and Drug Administration (FDA) for emergency contraception under the brand name "ella" on August 13, 2010. It is a selective progesterone receptor modulator (SPRM) that affects the progesterone receptors in the body.
Mechanism of Action of undefined
Ulipristal acetate, as a selective progesterone receptor modulator (SPRM), is prescribed to help manage the symptoms associated with uterine fibroids by reducing their size and alleviating related discomfort. It works by targeting the progesterone receptors in the body, which are involved in the growth of fibroids and the regulation of menstruation. This medication helps to control menstrual bleeding and decrease the size of fibroids, thus improving the quality of life for women with symptomatic uterine fibroids.
Uses of undefined
Ulipristal acetate is used for emergency contraception and the treatment of uterine fibroids.
undefined Drug administaration and Dosage available
Ulipristal acetate is typically used as a single oral dose for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse. It's usually taken as one tablet daily with or without food for a specified treatment period for uterine fibroid treatment. To ensure effectiveness, follow your healthcare provider's instructions precisely. If using for emergency contraception, take it immediately after unprotected sex. If taking for fibroids, adhere to the prescribed schedule and consult your doctor for guidance on any missed doses or concerns.
Warnings, Precautions and Side Effects of undefined
Ulipristal acetate comes with several warnings, including the risk of ectopic pregnancy, its potential impact on liver function, the possibility of allergic reactions, alterations in menstrual patterns, its incompatibility with breastfeeding and pregnancy, potential interactions with other medications, and its influence on hormonal contraception efficacy.
Caution is also advised for individuals with certain medical conditions, the age group under 18, and the risk associated with repeated use within a single menstrual cycle. Patients are urged to adhere to prescribed dosages and follow-up appointments and consult medical professionals promptly for severe symptoms or concerns.
Ulipristal acetate may lead to common side effects like headache, nausea, and abdominal discomfort. Less common but potentially serious side effects include severe abdominal pain, allergic reactions, and liver issues.
Word Of Advice
Ulipristal acetate should be approached carefully. Caution is advised for individuals with liver impairments, as the liver metabolizes the medication. Allergic reactions are possible, necessitating prompt medical attention if symptoms like rash, swelling, or difficulty breathing occur. The impact on menstrual cycles requires monitring, and any significant changes or irregular bleeding patterns should be discussed with a healthcare provider. This medication is not recommended during pregnancy or breastfeeding due to potential risks. Patients should inform their healthcare providers about their medications to avoid interactions. This medication can interact with certain medications, potentially affecting their effectiveness or causing adverse effects. Drugs that are strong CYP3A4 inducers or inhibitors, such as rifampicin and ketoconazole, can alter its metabolism, while hormonal contraceptives may be less effective if taken concurrently. Additionally, repeated use within a single menstrual cycle and its use in individuals under 18 should be carefully considered. Adherence to prescribed dosages, follow-up appointments, and seeking medical attention for any concerning symptoms is strongly advised.
Frequently Asked Question
- Allergan Inc., [Revised on 3rd Jul 2019] [Accessed on 26th Aug 2023], https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/2019-07-03-fibristal-pm-english.pdf
- Gedeon Richter Plc., Electronic Medicines Compendium (EMC), [Revised on Jan 2021] [Accessed on 26th Aug 2023], https://www.medicines.org.uk/emc/files/pil.3951.pdf
- Paweł Milart et al., Ulipristal acetate as a treatment option for uterine fibroids, Menopause Rev, 2017; 16(4): 133-136, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824685/pdf/MR-16-31511.pdf
- Ellis R. Levin, Wendy S. Vitek, and Stephen R. Hammes, Estrogens, Progestins, and the Female Reproductive Tract, Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13th Edition, 2018, 803-831.
- Watson Pharma, Inc, Food and Drug Safety Administration (FDA) [Revised on August 2008] [Accessed on 26th Aug 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s000lbl.pdf
The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.